Halozyme Therapeutics, Inc. $HALO Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lowered its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 44.4% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 61,279 shares of the biopharmaceutical company’s stock after selling 48,963 shares during the period. Mutual of America Capital Management LLC’s holdings in Halozyme Therapeutics were worth $3,188,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Alliancebernstein L.P. grew its holdings in shares of Halozyme Therapeutics by 4.8% in the first quarter. Alliancebernstein L.P. now owns 3,215,109 shares of the biopharmaceutical company’s stock valued at $205,156,000 after purchasing an additional 146,677 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Halozyme Therapeutics by 4.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,029,160 shares of the biopharmaceutical company’s stock worth $129,478,000 after acquiring an additional 95,600 shares in the last quarter. TD Asset Management Inc grew its holdings in Halozyme Therapeutics by 5.8% during the 1st quarter. TD Asset Management Inc now owns 1,451,842 shares of the biopharmaceutical company’s stock worth $92,642,000 after acquiring an additional 79,708 shares in the last quarter. Fuller & Thaler Asset Management Inc. grew its holdings in Halozyme Therapeutics by 27.3% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,130,019 shares of the biopharmaceutical company’s stock worth $72,107,000 after acquiring an additional 242,167 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec grew its holdings in Halozyme Therapeutics by 154.5% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 910,169 shares of the biopharmaceutical company’s stock worth $58,078,000 after acquiring an additional 552,590 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In related news, CFO Nicole Labrosse sold 2,227 shares of the company’s stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $77.95, for a total value of $173,594.65. Following the completion of the sale, the chief financial officer owned 22,079 shares in the company, valued at $1,721,058.05. This represents a 9.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $69.03, for a total transaction of $1,380,600.00. Following the completion of the sale, the chief executive officer owned 733,719 shares of the company’s stock, valued at approximately $50,648,622.57. This trade represents a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 108,227 shares of company stock worth $7,779,595 in the last 90 days. 2.40% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Morgan Stanley lowered their price target on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a report on Monday. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. The Goldman Sachs Group assumed coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They set a “neutral” rating and a $55.00 price target for the company. Benchmark boosted their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Finally, JPMorgan Chase & Co. upped their target price on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Five analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $72.89.

Halozyme Therapeutics Trading Up 1.7%

Shares of Halozyme Therapeutics stock opened at $66.89 on Friday. The company has a fifty day simple moving average of $71.73 and a 200-day simple moving average of $62.25. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $79.50. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. The stock has a market cap of $7.82 billion, a price-to-earnings ratio of 15.31, a PEG ratio of 0.35 and a beta of 1.16.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. During the same quarter in the prior year, the firm earned $0.91 EPS. Halozyme Therapeutics’s revenue for the quarter was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.